JP2010524939A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524939A5
JP2010524939A5 JP2010504079A JP2010504079A JP2010524939A5 JP 2010524939 A5 JP2010524939 A5 JP 2010524939A5 JP 2010504079 A JP2010504079 A JP 2010504079A JP 2010504079 A JP2010504079 A JP 2010504079A JP 2010524939 A5 JP2010524939 A5 JP 2010524939A5
Authority
JP
Japan
Prior art keywords
carbons
nuclear receptor
alkyl
receptor binding
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504079A
Other languages
English (en)
Japanese (ja)
Other versions
JP5815237B2 (ja
JP2010524939A (ja
Filing date
Publication date
Priority claimed from US11/785,251 external-priority patent/US8158828B2/en
Application filed filed Critical
Publication of JP2010524939A publication Critical patent/JP2010524939A/ja
Publication of JP2010524939A5 publication Critical patent/JP2010524939A5/ja
Application granted granted Critical
Publication of JP5815237B2 publication Critical patent/JP5815237B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504079A 2007-04-16 2008-04-16 核内受容体結合剤 Expired - Fee Related JP5815237B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/785,251 US8158828B2 (en) 2005-11-28 2007-04-16 Nuclear receptor binding agents
US11/785,251 2007-04-16
PCT/US2008/004908 WO2008130571A1 (en) 2007-04-16 2008-04-16 Nuclear receptor binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014033091A Division JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Publications (3)

Publication Number Publication Date
JP2010524939A JP2010524939A (ja) 2010-07-22
JP2010524939A5 true JP2010524939A5 (enExample) 2011-06-02
JP5815237B2 JP5815237B2 (ja) 2015-11-17

Family

ID=39876311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504079A Expired - Fee Related JP5815237B2 (ja) 2007-04-16 2008-04-16 核内受容体結合剤
JP2014033091A Expired - Fee Related JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014033091A Expired - Fee Related JP5913400B2 (ja) 2007-04-16 2014-02-24 核内受容体結合剤

Country Status (4)

Country Link
US (1) US8158828B2 (enExample)
JP (2) JP5815237B2 (enExample)
KR (2) KR101563609B1 (enExample)
WO (1) WO2008130571A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
FI3345607T3 (fi) * 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
WO2009076548A1 (en) * 2007-12-13 2009-06-18 Cytori Therapeutics, Inc. Methods of inhibiting tumor development using adipose-derived regenerative cells
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
US20100130457A1 (en) * 2008-11-14 2010-05-27 Immune Control, Inc. Phenothiazine Derivatives for Treatment of Asthma
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
KR101458539B1 (ko) * 2009-02-23 2014-11-10 지티엑스, 인코포레이티드 에스트로겐 수용체 리간드 및 그 이용 방법
WO2013043304A1 (en) * 2009-02-23 2013-03-28 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US20140057946A1 (en) * 2012-08-23 2014-02-27 Gtx Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
ES2907862T3 (es) * 2009-12-10 2022-04-26 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
CN106432137B (zh) 2010-12-22 2020-11-06 纽约市哥伦比亚大学理事会 组蛋白乙酰转移酶调节剂和其用途
EP2717688B1 (en) 2011-06-10 2017-12-13 The Trustees of Columbia University in the City of New York Uses of histone acetyltransferase activators
AU2012312902B2 (en) * 2011-08-23 2016-03-17 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2013064206A1 (de) * 2011-11-01 2013-05-10 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
HUE052574T2 (hu) 2012-07-13 2021-05-28 Oncternal Therapeutics Inc Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
WO2014037811A2 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
WO2014182944A1 (en) * 2013-05-08 2014-11-13 Mangat Harpal S Compositions and method for treatment of ischemic neuronal reperfusion injury
CN111346076A (zh) * 2014-07-24 2020-06-30 艾森潘帕克制药股份有限公司 使用顺式氯米芬治疗雄激素剥夺疗法诱导的热潮红和骨丢失
US20220054429A1 (en) * 2015-10-27 2022-02-24 Jay Pharma, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
WO2018208633A1 (en) * 2017-05-07 2018-11-15 China Medical University Methods and compositions for treating withdrawal syndrome
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE269213C (enExample)
US3413339A (en) * 1964-06-18 1968-11-26 Parke Davis & Co Amine compounds and methods for their production
FR1536400A (fr) 1967-07-05 1968-08-16 Salicylanilides
US3625972A (en) 1968-07-03 1971-12-07 Sterling Drug Inc N-phenylbenzanilides
US3960886A (en) 1968-07-03 1976-06-01 Sterling Drug Inc. Substituted N-arylanilines
FR2140645A1 (en) 1971-06-11 1973-01-19 Grace W R Ltd Oxidation stabilised ester lubricants - contg mixed tert aromatic amines
US3838131A (en) 1972-04-03 1974-09-24 Pfizer Di(dialkylamino alkoxy)phenanthridines as antiviral agents
US3838134A (en) 1972-04-03 1974-09-24 G Gauthier Phenanthridinones as antiviral agents
US4373017A (en) 1980-03-05 1983-02-08 Konishiroku Photo Industry Co., Ltd. Photosensitive compound and photosensitive material containing it
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
ATE148098T1 (de) 1991-02-21 1997-02-15 Sankyo Co Benzolderivate zum fördern der produktion des nervenwachstumsfaktors
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
WO1997034589A1 (en) 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease
WO1996008240A1 (en) * 1994-09-16 1996-03-21 President And Fellows Of Harvard College Use of aromatic halides for treating mammalian cell proliferation
GB9518994D0 (en) 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
AU1730497A (en) 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
JPH1171332A (ja) * 1997-06-17 1999-03-16 Sumitomo Chem Co Ltd トリフェニルメタン誘導体およびその用途
US20020156301A1 (en) 1997-06-17 2002-10-24 Sumitomo Chemical Co., Ltd. Triphenylmethane derivatives and use thereof
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6166013A (en) 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
JP2002542187A (ja) 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
JP4320089B2 (ja) 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
DE19961372A1 (de) 1999-12-17 2001-06-21 Merck Patent Gmbh Verfahren zur Herstellung kombinatorischer Bibliotheken arylsubstituierter Amine
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
AU2001292320A1 (en) 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20040082813A1 (en) 2001-03-16 2004-04-29 Toshihiro Iwakuma Method for producting aromatic amino compound
JP2002322162A (ja) 2001-04-26 2002-11-08 Kyowa Hakko Kogyo Co Ltd チアゾリジン誘導体
US20060287282A1 (en) 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
EP1666033B1 (en) 2001-11-29 2008-12-31 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
CA2492907A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
JP2006508061A (ja) 2002-09-20 2006-03-09 ファイザー・プロダクツ・インク エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
BR0316098A (pt) * 2002-11-08 2005-09-27 Huawei Tech Co Ltd Método, sistema, e um terminal para executar a interação de informações de apresentação dos usuários de lan sem fio
JP2004307380A (ja) 2003-04-04 2004-11-04 Mitsubishi Chemicals Corp 新規化合物、電荷輸送材料、有機電界発光素子材料および有機電界発光素子
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
EA201500845A1 (ru) 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
KR20090030345A (ko) 2006-07-19 2009-03-24 더 오하이오 스테이트 유니버시티 리서치 파운데이션 선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도

Similar Documents

Publication Publication Date Title
RU2016103139A (ru) Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
RU2434865C2 (ru) Аналоги тетрагидрохинолина в качестве мускариновых агонистов
RU2012105467A (ru) Триазолопиридиновое соединение и его действие в качестве ингибитора пролилгидроксилазы и индуктора выработки эритропоэтина
RU2012137501A (ru) Сигма-лиганды для применения при профилактике и/или лечении послеоперационной боли
JP2012530758A5 (enExample)
JP2011527334A5 (enExample)
JP2009511490A5 (enExample)
JP2004524316A5 (enExample)
JP2011137006A5 (enExample)
JP2010536887A5 (enExample)
JP2006516622A5 (enExample)
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2015142102A (ru) Соединение для лечения рака
JP2011521938A5 (enExample)
JP2013520473A5 (enExample)
JP2014015465A5 (enExample)
JP2013508288A5 (enExample)
JP2019515643A5 (enExample)
TNSN07016A1 (en) Indole-2-carboxamidine derivatives as nmda receptor antagonists
RU2015147509A (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
RU2011137324A (ru) Лиганды рецепторов эстрогенов и способы их применения
AU2006318400C1 (en) Nuclear receptor binding agents
JP2017525740A5 (enExample)